发明申请
US20110251593A1 In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs
有权
用临床试验的FDA批准的药物的目标组合的造血干细胞的体内和体外扩增
- 专利标题： In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs
- 专利标题（中）： 用临床试验的FDA批准的药物的目标组合的造血干细胞的体内和体外扩增
-
申请号： US13084180申请日： 2011-04-11
-
公开(公告)号： US20110251593A1公开(公告)日： 2011-10-13
- 发明人: Peter S. Klein , Jian Huang
- 申请人： Peter S. Klein , Jian Huang
- 专利权人： The Trustees of the University of Pennsylvania
- 当前专利权人： The Trustees of the University of Pennsylvania
- 主分类号： A61M37/00
- IPC分类号： A61M37/00 ; A61K35/28 ; A61P35/00 ; A61P7/06 ; A61P19/08 ; C12N5/0775 ; A61P35/02
摘要：
The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions.
公开/授权文献
信息查询
IPC分类:
